Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship-Reference-Cited by-同舟云学术

Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship

Published:2020-05-25 Issue:13 Volume:47 Page:3018-3032
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Chiesa C.^ORCID,Mira M.,Bhoori S.,Bormolini G.,Maccauro M.,Spreafico C.,Cascella T.,Cavallo A.,De Nile M. C.,Mazzaglia S.,Capozza A.,Tagliabue G.,Brusa A.,Marchianò A.,Seregni E.,Mazzaferro V.

Funder

BTG biocompatibles

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-020-04845-4.pdf

Reference32 articles.

1. Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol. 2014;19:4–210. https://doi.org/10.3389/fonc.2014.00210.

2. Sposito C, Mazzaferro V. The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future. Hepatobiliary Surg Nutr. 2018;7(6):487–9.

3. Bastiaannet R, Kappadath SC, Kunnen B, Braat AJAT, Lam MGEH, de Jong HWAM. The Physics of Radioembolization. Eur J Nucl Med Mol Im Physics. 2018;5(1):22.

4. Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, et al. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. J Nucl Med. 2016;57(11):1672–8.

5. Jadoul A, Bernard C, Lovinfosse P, Gérard L, Lilet H, Cornet O, et al. Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumours. Eur J Nucl Med Mol Imaging. 2020;47(4):828–37.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-05

2. Precision individual dosimetry in Yttrium-90 transarterial radioembolization in the presence of Au nanoparticles;Radiation Physics and Chemistry;2024-09

3. Advancing Radioembolization Through Personalized Dosimetry;Advances in Clinical Radiology;2024-09

4. PET/CT-Based Absorbed Dose Maps in⁹⁰Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI;Journal of Nuclear Medicine;2024-07-03

5. Dose–effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization;European Journal of Nuclear Medicine and Molecular Imaging;2024-02-19